Aldagen, Inc. · Durham, NC United States (NASDAQ: ALDH)
| 2810 Meridian Pkwy., Ste. 148 | Phone: 919-484-2571 |
| Durham, NC | Fax: 919-484-8792 |
| 27713 | |
| United States | 
Map This Company |
Aldagen, Inc. Rankings
More Companies in These Related Industries: Surgical & Medical Instrument MfgCompany Description
Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.
Aldagen, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Private - NASDAQ: ALDH Single Location |
|---|---|
| Fiscal Year-End | December |
| 2009 Employees | 25 |
Executives
12 executives listed for Aldagen, Inc.'s Durham, NC location.
| Chairman | Richard Kent | |
|---|---|---|
| CEO | Lyle Hohnke | |
| EVP and Chief Business Officer | Edward Field |